EGFR and lung carcinoma: Cleavage of DSG2 was mediated by junction opener 1 (JO-1), and downstream signaling combined with a monoclonal antibody targeting EGFR, Erbitux, provide better therapeutic outcomes in EGFR-positive lung cancer [30].